{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:37:42Z","timestamp":1791657462195,"version":"4.3.4"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jtha.2023.12.027","type":"journal-article","created":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T21:29:37Z","timestamp":1703885377000},"page":"915-918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["The underevaluated impacts of the therapeutic revolution of hemophilia on women and girls"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5429-8437","authenticated-orcid":false,"given":"Cedric","family":"Hermans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8270-8819","authenticated-orcid":false,"given":"Evelien","family":"Krumb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3354-3880","authenticated-orcid":false,"given":"Dawn","family":"Rotellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3310-328X","authenticated-orcid":false,"given":"Glenn F.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.12.027_bib1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3324\/haematol.2019.232132","article-title":"Hemophilia therapy: the future has begun","volume":"105","author":"Mannucci","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2023.12.027_bib2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtha.2022.12.029","article-title":"Hemophilia treatment innovation: 50 years of progress and more to come","volume":"21","author":"Mannucci","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.12.027_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bjh.18379","article-title":"Current and future therapies for haemophilia\u2014beyond factor replacement therapies","volume":"200","author":"Nogami","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2023.12.027_bib4","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/rth2.12337","article-title":"Bispecific antibodies and advances in non-gene therapy options in hemophilia","volume":"4","author":"Shima","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.12.027_bib5","first-page":"191","article-title":"Concizumab as a subcutaneous prophylactic treatment option for patients with hemophilia A or B: a review of the evidence and patient\u2019s perspectives","volume":"13","author":"Pasca","year":"2022","journal-title":"J\u00a0Blood Med"},{"key":"10.1016\/j.jtha.2023.12.027_bib6","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/bjh.18495","article-title":"Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: phase II study results","volume":"200","author":"Mahlangu","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2023.12.027_bib7","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/S2352-3026(23)00057-1","article-title":"Fitusiran prophylaxis in severe haemophilia without inhibitors","volume":"10","author":"Jim\u00e9nez-Yuste","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2023.12.027_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100179","article-title":"Antithrombin lowering in hemophilia: a closer look at fitusiran","volume":"7","author":"Young","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.12.027_bib9","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/blood.2019003777","article-title":"Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues","volume":"138","author":"Leebeek","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.12.027_bib10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/hae.13862","article-title":"Achieving the unimaginable: health equity in haemophilia","volume":"26","author":"Skinner","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.12.027_bib11","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/rth2.12494","article-title":"Patient selection for hemophilia gene therapy: real-life data from a single center","volume":"5","author":"Krumb","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.12.027_bib12","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/hae.14807","article-title":"Towards achieving a haemophilia-free mind","volume":"29","author":"Hermans","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.12.027_bib13","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1182\/bloodadvances.2020002364","article-title":"First report of emicizumab use in\u00a0a female patient with severe hemophilia A","volume":"4","author":"Verstraete","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.12.027_bib14","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/hae.14379","article-title":"European Haemophilia Consortium (EHC) and the European Association for Haemophilia and Allied Disorders (EAHAD). European principles of care for women and girls with inherited bleeding disorders","volume":"27","author":"van","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.12.027_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/rth2.12468","article-title":"Sexism in the management of bleeding disorders","volume":"5","author":"Weyand","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.12.027_bib16","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.transci.2019.08.013","article-title":"Women and inherited bleeding disorders \u2013 a review with a focus on key challenges for 2019","volume":"58","author":"Winikoff","year":"2019","journal-title":"Transfus Apher Sci"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623009297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623009297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T06:08:24Z","timestamp":1744438104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623009297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1538783623009297"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.12.027","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The underevaluated impacts of the therapeutic revolution of hemophilia on women and girls","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.12.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}